Pulmonx Corporation LUNG
- Market cap
- $81.6M
- P/E
- 0.0×
Follow LUNG
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 37.64 | 28.87 | 4.07 | 7.23 | 5.46 | 1.31 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 69.48 | 68.76 | 36.26 | 14.28 | 14.84 | 9.37 |
High Price
|
|||
| — | — | — | 202 | 170 | 160 | 269 | 279 | 291 | 296 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 20 | 33 | 33 | 48 | 54 | 69 | 84 | 90 |
Revenue
|
|||
| — | — | 61.42% | 68.77% | 64.77% | 73.59% | 74.29% | 73.90% | 74.00% | 74.19% |
Gross Margin
|
|||
| — | — | (18) | (20) | (32) | (48) | (59) | (60) | (56) | (53) |
EBT
|
|||
| — | — | (92.32%) | (62.40%) | (97.82%) | (99.80%) | (109.15%) | (87.76%) | (66.71%) | (58.98%) |
EBT Margin
|
|||
| — | 0 | (18) | (21) | (32) | (49) | (59) | (61) | (56) | (54) |
Net Income
|
|||
| — | — | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
Depreciation
|
|||
| — | — | 11.94 | 18.35 | 3.21 | 1.34 | 1.45 | 1.81 | 2.14 | 2.22 |
Revenue/Sh
|
|||
| — | — | (11.03) | (11.66) | (3.16) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
Earnings/Sh
|
|||
| — | — | (10.98) | (11.69) | (3.01) | (1.15) | (1.22) | (0.99) | (0.81) | (0.80) |
Cash Flow/Sh
|
|||
| — | — | (0.18) | (0.41) | (0.09) | (0.10) | (0.04) | (0.02) | (0.04) | (0.01) |
Capex/Sh
|
|||
| — | — | (11.16) | (12.10) | (3.10) | (1.25) | (1.25) | (1.01) | (0.84) | (0.81) |
Free CF/Sh
|
|||
| — | — | (15.99) | 10.11 | 22.20 | 5.35 | 4.15 | 3.12 | 2.19 | 1.33 |
Book Value/Sh
|
|||
| — | — | 2 | 2 | 10 | 36 | 37 | 38 | 39 | 41 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 3.33 | 3.33 | 21.48 | 23.93 | 5.18 | 7.02 | 3.17 | 0.99 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 3.11 | 6.00 | 1.80 | 4.08 | 3.09 | 1.66 |
PB Ratio
|
|||
| — | — | 3.58 | 3.58 | 14.98 | 20.61 | 2.87 | 5.86 | 2.40 | 0.63 |
EV/Sales
|
|||
| — | — | (4.36) | (4.36) | (15.54) | (22.15) | (3.31) | (10.47) | (6.09) | (1.74) |
EV/FCF
|
|||
| — | — | (18) | (21) | (31) | (41) | (45) | (38) | (32) | (32) |
Op' Cash Flow
|
|||
| — | — | 0 | (1) | (1) | (4) | (1) | (1) | (1) | 0 |
Capex
|
|||
| — | — | (19) | (21) | (32) | (45) | (46) | (38) | (33) | (33) |
FCF
|
|||
| — | — | 3 | 27 | 237 | 190 | 150 | 127 | 112 | 82 |
Working Cap'
|
|||
| — | — | 34 | 15 | 19 | 20 | 17 | 37 | 37 | 37 |
Total Debt
|
|||
| — | — | 29 | (13) | (213) | (161) | (124) | (80) | (65) | (33) |
Net Debt
|
|||
| — | — | (27) | 18 | 226 | 193 | 154 | 118 | 86 | 54 |
Sh' Equity
|
|||
| — | — | (246.17%) | (60.41%) | (20.32%) | (19.51%) | (27.48%) | (32.76%) | (33.11%) | (36.97%) |
ROA
|
|||
| — | — | (349.72%) | (221.87%) | (150.98%) | (90.74%) | (122.32%) | (101.28%) | (169.73%) | (158.98%) |
ROIC
|
|||
| — | — | 10.42% | 11.67% | (166.33%) | (23.21%) | (33.94%) | (44.68%) | (55.25%) | (77.19%) |
ROE
|
|||
Pulmonx Corporation peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SERA Sera Prognostics, Inc. | $83.2M | 0.0× | Compare |
| HYPR Hyperfine, Inc. | $84.4M | 0.0× | Compare |
| LNSR LENSAR, Inc. | $86.9M | 2.4× | Compare |
| ZOMDF Zomedica Corp. | $95.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CVRX CVRx, Inc. | $67.4M | 0.0× | Compare |
| ECOR electroCore, Inc. | $102.3M | 0.0× | Compare |
| MYO Myomo, Inc. | $64.6M | 0.0× | Compare |
| OM Outset Medical, Inc. | $58.8M | 0.0× | Compare |
Pulmonx Corporation (LUNG) key facts
- Pulmonx Corporation (LUNG) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024.
- Pulmonx Corporation reported a net loss of $54.0 million, or a loss of $1.33 per share, for fiscal 2025.
- As of September 25, 2026, LUNG traded at $1.91, a market capitalization of $81.6 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.9× sales.
- Return on equity was −77.2% and debt-to-equity 0.95.
Pulmonx Corporation (LUNG) Latest News
15 Aug
Pulmonx rebuilds sales force to target growth and schedules AeriSeal launch for next year. Sales force rebuild plus AeriSeal launch next year will drive major revenue growth and market expansion for Pulmonx.
7 Aug
Pulmonx (LUNG) released its Q2 2026 earnings call transcript covering financial results, operational updates, and forward guidance. Quarterly earnings details may shift near-term sentiment and valuation but rarely transform long-term company trajectory.
3 Aug
Pulmonx (LUNG) stock receives Buy upgrade from analysts, pointing to expected gains in investor interest and share performance. Buy rating upgrade can moderately lift near-term investor sentiment and trading activity for Pulmonx shares.
30 Jul
Pulmonx Corporation held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance for the medical device business. Quarterly earnings releases and guidance typically produce moderate short-term effects on valuation and sentiment without altering long-term strategy.
29 Jul
Pulmonx Q2 earnings call covered financial results, operational updates, and forward outlook for the company. Q2 earnings details offer moderate insight into financial performance and near-term trajectory.
Pulmonx Corporation (LUNG) reported its second quarter 2026 financial results. Quarterly earnings release supplies performance metrics that can shift near-term investor views and valuation.
30 Apr
Pulmonx (LUNG) released Q1 2026 earnings call transcript detailing financial results, operational updates, and future guidance. Q1 earnings transcript discloses financial performance, strategic updates, and outlook that can significantly sway investor sentiment and stock trajectory.
Pulmonx Corporation released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings summary discloses key financial metrics and guidance that significantly shape investor expectations and stock trajectory.
Pulmonx Corp (LUNG) Q1 2026 earnings call highlights navigating operational challenges through strategic initiatives amid mixed financial results. Q1 2026 earnings highlights detail strategic responses to challenges, significantly impacting financial trajectory and investor sentiment.
29 Apr
Pulmonx Corporation (LUNG) released Q1 earnings call highlights detailing financial results, revenue growth, and forward guidance. Q1 earnings highlights provide critical financial data and guidance that significantly shape Pulmonx's market performance and investor outlook.
Pulmonx Corporation reported first quarter 2026 financial results. Quarterly financial results disclosure significantly influences stock performance and investor sentiment for Pulmonx.
Pulmonx Corporation (LUNG) reported a Q1 net loss of $0.36 per share but beat revenue estimates with $24.4 million, up 25% year-over-year, driven by strong procedure growth and international expansion. Q1 revenue beat despite loss highlights operational growth but underscores ongoing profitability challenges with moderate impact on financial trajectory.
19 Apr
Pulmonx Corporation (LUNG) investment narrative resets around lower price target due to heightened execution risks. Lower target and execution risks significantly pressure valuation and investor sentiment.
4 Apr
Pulmonx (LUNG) Q4 results and new guidance shift the company's investment story, highlighting changes in growth trajectory, market positioning, and future outlook. Q4 results and new guidance represent major strategic updates that could significantly alter Pulmonx's trajectory and investor sentiment.
21 Mar
Pulmonx Corporation (LUNG) investment narrative resets around heightened execution risks and revised fair value assumptions, prompting investor reevaluation of the company's trajectory. Execution risks and fair value adjustments moderately influence Pulmonx's market sentiment and valuation without fundamentally altering long-term prospects.
5 Mar
Pulmonx Corporation released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings call summaries reveal key financial metrics, revenue growth, and strategic outlook that significantly influence Pulmonx Corporation's stock performance and investor confidence.
Pulmonx Corp reported Q4 2025 earnings with strategic restructuring, sales force realignment for efficiency, revenue growth highlights, and outlook for improved performance amid market challenges. Strategic restructuring and sales force changes constitute major operational shifts expected to significantly alter Pulmonx's efficiency, financial trajectory, and investor sentiment.
4 Mar
Pulmonx Corporation's Q4 earnings call highlights key financial results, revenue growth, operational updates, and forward-looking guidance for 2024. Q4 earnings highlights detail financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.
Pulmonx (LUNG) released Q4 2025 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings transcript discloses full-year financials, growth metrics, and guidance shaping investor expectations and market trajectory.
Pulmonx Corporation reported fourth quarter and full year 2025 financial results. Quarterly and annual financial results directly shape investor sentiment, revenue guidance, and stock trajectory.
Pulmonx Corporation closed a credit facility providing up to $60 million to support operations and growth. Closing a $60 million credit facility bolsters Pulmonx's financial flexibility for expansion and operational needs.
Pulmonx Corporation (LUNG) reported a Q4 net loss but exceeded revenue estimates. Q4 revenue beat despite net loss indicates moderate financial influence with balanced investor sentiment.
10 Jan
Pulmonx Corporation is experiencing a shift in narrative following a target price cut and the return of leadership. The company's strategic direction and market positioning are under scrutiny as investors reassess its growth potential and operational effectiveness. This change comes amid broader market dynamics that could influence investor sentiment and future performance. The leadership return and target cut may moderately influence investor sentiment and operational aspects, but the overall effect is expected to be limited.
25 Dec
Pulmonx Corporation is undergoing leadership changes that may influence its valuation. Analysts are revising their forecasts, reflecting shifts in market sentiment and expectations regarding the company's future performance. These developments could impact Pulmonx's strategic direction and investor confidence. Leadership changes and analyst revisions are likely to significantly affect investor sentiment and the company's strategic trajectory.
11 Dec
Pulmonx Corporation is experiencing a shift in investor sentiment due to new catalysts, including advancements in its product offerings and potential market expansion. The company is focusing on enhancing its technology and addressing regulatory challenges, which could lead to improved financial performance. Analysts are optimistic about the future trajectory of Pulmonx, highlighting the importance of these developments in shaping the company's competitive position. Significant product advancements and market expansion efforts are likely to alter the company's trajectory and investor sentiment.
3 Dec
Pulmonx Corporation (LUNG) is highlighted as a promising penny stock for December 2025, with potential for growth driven by advancements in its lung treatment technologies. The company is positioned to benefit from increasing demand for innovative medical solutions in respiratory care, which may enhance its market presence and investor interest. Analysts suggest that Pulmonx's unique offerings could lead to significant financial performance improvements in the coming years. Advancements in lung treatment technologies and increasing demand in respiratory care are likely to significantly impact Pulmonx's market performance.
13 Nov
Recent developments at Pulmonx Corporation indicate a shift in market dynamics, with new product innovations and strategic partnerships enhancing its competitive position. The company is focusing on expanding its reach in the lung health sector, which could lead to increased revenue streams and improved patient outcomes. Analysts are optimistic about the potential for growth as Pulmonx navigates regulatory landscapes and adapts to changing healthcare demands. Strategic partnerships and product innovations are likely to significantly impact Pulmonx's market position and future performance.
Pulmonx Corporation reported its Q3 2025 earnings, highlighting challenges in growth and market dynamics. The company is navigating competitive pressures and regulatory hurdles while focusing on product innovation and strategic initiatives to enhance its market position. Despite these challenges, management remains optimistic about future prospects and ongoing projects aimed at improving financial performance. Challenges in growth and market dynamics may moderately influence financial performance and competitive positioning.
12 Nov
Pulmonx Corporation reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational achievements. The company continues to focus on expanding its product offerings and market presence, aiming to enhance its competitive position in the medical device sector. Management provided insights into future strategies and anticipated market trends, indicating a positive outlook for the upcoming quarters. Significant revenue growth and strategic initiatives are likely to impact Pulmonx's future performance and market positioning.
Pulmonx Corporation (LUNG) reported a loss for Q3 but exceeded revenue estimates. The company continues to focus on its innovative lung treatment solutions, which may influence future performance despite the current financial setback. The revenue beat indicates potential for growth, but the reported loss suggests challenges that may limit overall impact.